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Abstract 
Background and Purposes - Successful advances in the treatment of rheumatoid arthritis rely on enrolment of 
patients  into  clinical  trials  with  novel  agents.  The  aim  of  this  study  was  to  assess  the  patients’  perspectives  and 
motivators to participate in clinical trials. 
Methods  –  Consecutive  patients  with  rheumatoid  arthritis  attending  three  rheumatology  departments  in 
Romania  underwent  structured  questionnaire  interview  regarding  the  motivation  /possible  causes  of  acceptance  or 
drawbacks to participate in a clinical trial. 
Results  –A total  of 96 patients,  mean age  48,  30%  men 70% women answered. Response rate was 95%. 
Previous participation in other clinical trials was 23%. Patients were highly motivated to participate in order to help 
themselves or other patients and to enhance the knowledge about the disease. Patients were prone to ask for advice 
about their enrolment in the study from the family and their current physicians, including the general practitioner. The 
need for supplementary information about the study was felt because they had not dared to ask for the information, 
although they trusted their current doctor. A high percentage considered payment and free complete blood tests as a 
stimulus,  especially  among  patients  with  lower  levels  of  education  (p=0.03,  Fisher’s  ANOVA).  Advertising  for 
investigational medical product for purposes of patient recruitment was important for 57 %, not only for safety or trust, 
but also for transparency and as a tool to get information. 73% of the persons agreed to the usefulness of patients 
association. 26% of them were willing to be actively involved, especially to report and include adverse events in the 
study settings. 58% were motivated if they knew other patients were consulted. Patients were not motivated because of 
the adverse events, placebo effect, treatment discontinuation, limited previous experience, availability of alternative 
therapies and doctor reimbursement for the study. 
Conclusions – The current study suggests that awareness of factors (positive and negative) which influence 
motivation to participate in a clinical trial may help to refine patient’s education and to consider new strategies for 
future trials. 
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Introduction  
 
The  clinical  research  trials  with  novel 
therapies are intended to bring benefits to society 
and  future  patients  by  advancing  medical 
knowledge.  The  research  done  has  increased 
dramatically in the past 15 years, as researchers in 
the  public  and  private  sectors  have  strived  to 
develop and bring to the public a wider range of 
diagnostic  tests  and  treatment  than  ever.  Thus, 
more patients than ever are needed to participate 
in trials. Although the general public expects and 
demands  that  the  biomedical  community  should 
develop new, safe and effective approaches to the 
treatment of different diseases, the same public is 
not  aware  of  the  important  role  that  public 
participation plays in the development of medical 
advances. From this point of view patient accrual 
to clinical trials is a difficult problem [1], [2-4].  
In the mean time,  although “new” often 
implies  “better”,  the  fact  is  that  until  clinical 
research on a new treatment is complete, we do 
not know if it works better, the same as, or worse 
than  already  available  standard  therapies.  The 
researches  cannot  guarantee  that  the  treatment 
under  investigation  will  provide  a  benefit. 
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informed decision about whether to participate in 
a  clinical  trial  or  not  can  often  be  complicated. 
Altruism  is  cited  by  many  to  be  the  major 
motivating  factor  for  participating  in  clinical 
research [5] but may not be the sole motivating 
factor [6]. A lot of studies have investigated the 
motivations  and  inhibiting  factors  for  patients 
participating  in  phase  I  and  phase  II  cancer 
clinical  trials  [7],  but  there  are  only  a  few 
assessing  the  patients  with  rheumatoid  arthritis 
and their perspectives regarding the participation 
in the research. 
Our  study  aims  to  assess  the  patients’ 
perspectives  and  motivators  to  participate  in 
clinical trials. 
 
Material and methods 
 
Consecutive  patients  with  rheumatoid 
arthritis  attending  three  rheumatology 
departments  during  the  study  period  (October 
2007 –March 2008) were invited to take part in 
this  questionnaire  survey.  The  local  ethical 
committee approved the study design and the final 
format of the questionnaire. 
The  survey’s  investigators  asked  the 
patients  if  they  agreed  to  participate  in  a 
questionnaire  survey  that  would  take  about  15 
minutes to be completed. Each patient underwent 
a  structured  interview  using  a  questionnaire 
designed to assess the patients’ perspectives and 
motivators  to  participate  in  clinical  trials  with 
novel  biologic  agents.  We  stressed  that 
participation  was  voluntary  and  that  all 
information would be treated in confidence. The 
questionnaire was completed in the absence of the 
research nurse and was delivered to the clinic by 
each individual.  
 
Study instruments  
 
The  questionnaire  was  developed  by 
authors  and  was  piloted  with  10  other  different 
patients to ensure the clarity of meaning. The final 
format  of  the  questionnaire  consisted  of  13 
questions (open and close-ended questions).  The 
structured  questionnaire  is  available  on  request. 
Parameters  such  as  sex,  age,  marital  status  (single, 
married,  separated/divorced/widowed),  employment 
(full/part-time  employment,  unemployed,  housewife, 
retired),  educational  level  (high  school,  college, 
university/postgraduate),  disease  duration,  were  also 
recorded. 
 
Statistical analysis 
 
The  primary  statistical  analysis  was 
intended  to  be  descriptive.  Continuous  variables 
were  described  as  the  mean  +/-  SD  (standard 
deviation). Categorical variables were reported as 
percentages.  The  chi-square  test  was  used  to 
analyze categorical variables. One way ANOVA 
was  used  to  investigate  differences  between 
means.  P<0.05  was  considered  statistically 
significant.  Data  was  analyzed  using  SPSS  for 
Windows (version 13.0 Program). 
 
Results 
Participants 
 
96  consecutive  and  consenting  patients 
with rheumatoid arthritis agreed to participate in 
the  survey  (70%  women,  30%  men).  Mean  age 
was 48+/-13 years old, and mean disease duration 
was 11+/-9 years. 37% of them were retired. Most 
of them had medium educational level (73%). The 
response rate was 95% (96 out of 101 patients). 
Table 1 shows the demographic characteristics of 
the participants. 
 
Characteristics  Number  Percent 
Gender 
-  Male 
-  Female 
 
29 
67 
 
30 
70 
Age group (years old) 
-  20-29 
-  30-39 
-  40-49 
-  50-59 
-  60-69 
-  70-79 
 
13 
13 
16 
35 
19 
0 
 
13 
13 
16 
36 
20 
0 
Marital status 
-  Single 
-  Married 
-  Separated/divorced/ 
        widowed 
 
11 
80 
5 
 
11 
83 
5 
Education 
-  High school 
-  College 
-  University/ 
        Postgraduate 
 
58 
12 
26 
 
60 
13 
27 
Employment 
-  Full/part-time 
employment 
-  Unemployed 
-  Housewife 
-  Retired 
 
41 
 
3 
16 
36 
 
43 
 
3 
17 
37 
Previous trial participation 
-  Yes 
-  No 
 
22 
74 
 
23 
77 
 
 
 
Previous  participation  in  clinical 
trials 
 
23%  of  the  patients  were  involved  in 
previous randomized controlled clinical trials with 
medication for rheumatoid arthritis. All of them 
have  signed  a  written  informed  consent.  Only 
87%  of  them  received  a  copy  of  the  written 
Table 1. Demographics of the patients (N=96) 
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informed  consent  for  the  general  practitioner. 
When  they  had  been  asked  about  „How  much 
time  did  you  have  to  read  it  ?”  they  answered: 
14% (13) less than 10 minutes, 29% (28) less than 
1 hour, 57% (55%) one day. 47% of them felt the 
need for advice. 37 % of them asked the general 
practitioner  for  advice,  30%  asked  the  family, 
23%  other  patients  and  17%  pharmacists.  They 
had been asked „Why did you ask for advice?” 
10%  of  them  asked  for  advice  because  they 
needed  more  information  about  the  trial,  13% 
mentioned fear of „unknown” and 17% of them 
reported the need for reassurance in making the 
decision. Other reasons were mentioned as well: 
„I  need  a  second  opinion  from  someone  not 
involved”,  „I  didn’t  understand  the  medical 
language  that  doctor  used”,  I  thought  of  being 
„guinea pigs”. Previous clinical trials participation was 
greater  in  patients  retired  (p=0.04).There  was  no 
significant  correlation  between  disease  duration 
(p=0.2) and educational level (p=0.5). These patients 
were motivated by the desire to help gather data about 
the disease (p=0.013) and they were also prone to be 
involved  in  establishing  objectives  in  future  clinical 
trials. (p=0.04).  
 
Motivators  for  future  participation 
in clinical trials 
 
All  participants  answered  the  closed 
question  „Can  you  tell  us  the  reasons  why  you 
would participate in a future clinical trial?”. Most 
of them (90%) indicated hope of the health benefit 
as  the  most  important  motivating  factor  in  their 
decision  to  participate  in  the  trial.  Many 
participants  gave  altruistic  reasons  as  „helping 
others  to  get  better”  (77%)  or  „helping  in 
gathering  new  data  about  the  disease”  (83%). 
Other  important  motivating  reasons  were  the 
„trust in the physician” (72%) and „easy access to 
free complete laboratory tests” (63%). Only a few 
patients pointed on „getting paid for participation” 
(27%), and „maintaining a good relation with the 
doctor” (17%) as possible reasons to participate in 
a  clinical  trial.  Patients  with  lower  levels  of 
education  evoked  free  blood  tests  (63%)  and 
payment (27%) (ANOVA, p=0.03, p=0.0004) as 
motivators  for  future  participation  in  clinical 
trials. 
 
Question  Yes        (%) 
Can you tell us the reasons why you would participate in a future clinical trial?   
-  help me to get better  86         (90) 
-  help others to get better  74         (77) 
-  gather new data about the disease  80         (83) 
-  getting paid for participation  26         (27) 
-  easy access to free complete laboratory tests  60         (63) 
-  maintain a good relation with the doctor  16          (17) 
-  trust in the physician  69         (72) 
 
 
 
Sources of information as motivator 
for clinical trials 
 
57%  of  them  considered  that  media 
promotion  (in  a  newspaper,  on  the  internet,  on 
TV) of the clinical trial would raise clinical trial 
participation  because  it  would  make  them  more 
confident about it (37%). 
73% of them considered that being aware 
and  receiving  information  about  clinical  trials 
from social leagues would improve the patients’ 
participation  in  clinical  trials.  58%  of  them 
mentioned that they would be more confident if 
they knew the patients have been consulted before 
the  trial  began.  26%  of  them  wished  they  were 
involved  in  the  establishment  of  the  trial 
objectives and 10% in making clinical decisions 
regarding the trial. 17% were glad to have brought 
a relative to the consultation at the moment they 
received the information. 
 
Disincentives (drawbacks) for future 
participation in clinical trials (Table 3) 
 
When  the  participants  had  been  asked 
„Which  of  the  following  reasons  would  you  be 
negatively influenced by to participate in a future 
clinical trial?” the answers were: „potential side 
effects of the investigational product” (73%), „the 
chance of being randomized to placebo” (50%), 
and  „limited  previous  experience  with  the 
investigational  product”  (53%)  These  were  the 
main  reasons  for  being  skeptic  regarding  the 
participation in the clinical trial. The „availability 
of reasonable alternative therapies” (43%) as well 
Table 2. Motivator for participation in clinical trials 
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as  „treatment  discontinuation  at  the  end  of  the 
trial”  (33%)  were  also  disincentives  for 
participation. Only a small number of participants  
 
mentioned  „payments  to  clinicians  for  patients’ 
recruitment”  (13%)  and  „disruption  of  daily 
routine” (13%) as discouragements. 
Question     Yes        (%) 
Which of the following reasons would you be negatively influenced by to 
participate in a future clinical trial? 
 
 
Availability of reasonable alternatives therapies    45        (43) 
Limited previous experience with the investigational product    55        (53) 
Potential side effects of the investigational product    76        (73) 
The chance of being randomized to placebo    52        (50) 
Treatment discontinuation at the end of the trial    34        (33) 
Too much blood drawn during the trial    14        (13) 
Disruption of daily routine    14        (13) 
Transportation problems    14        (13) 
Payments to clinicians for patients recruitment    14        (13) 
 
 
 
 
 
Discussion 
 
Attitude  towards  clinical  research  was 
positive. Both personal and altruistic motives for 
participation were highly rated. Just like in other 
studies [8], the patients stated their motivation to 
participate  was  to  help  others,  to  improve  their 
own health, and to contribute to medical science 
but also the trust in the doctor’s request. Our data 
also showed the need for education programs in 
order to raise awareness, reduce fears, and dispel 
myths about clinical trials [9]. Another aspect that 
arose  is  the  importance  of  the  advertisement  of 
research  studies  that  may  increase  patient 
participation rates [10]. In the same time, giving 
people more information and more time to reflect 
tends to be associated with a lower consent rate. 
Although divulging less information seems to be 
associated with less anxiety, there is evidence of 
an  interaction  with  knowledge  -  high  levels  of 
knowledge  are  significantly  associated  with  less 
anxiety.  There  is  some  evidence  to  suggest  that 
there is an optimal amount of information which 
enhances  patient’s  understanding  and  which,  in 
turn, reduces anxiety [11].  
The  most  common  reasons  given  for 
unwillingness  to  participate  were  the  ones 
concerning  the  trial  setting;  a  dislike  of 
randomization,  presence  of  a  placebo  group, 
potential  side  effects.  The  fear  of  the  unknown 
and  resentments  towards  randomization  as 
primary  reasons  for  nonparticipation  were  also 
documented  [12].  A  number  of  patients  had  a 
negative  response  to  the  placebo.  Previous 
research has documented negative attitude about 
placebo, as a reason for a low rate of enrolment in 
clinical trials [13], [14], [15]. This fact could be 
reasonably managed by showing that patients on 
placebo  will  receive  the  standard  care  for  their 
stage of disease. A minority was concerned with 
potential  conflicts  of  interests.  The  clinical 
research funding mechanisms and the business of 
clinical research are also aspects which should be 
discussed with the participants in clinical trials, in 
order to build trust with the researchers and help 
participants  to  feel  more  comfortable  and 
confident to participate in the research [16]. 
A  small  number  of  patients  mentioned 
paying  to  participate  in  clinical  trials  as  a 
motivator  factor,  but  this  aspect  is  ethically 
controversial.  Halpern  et  co.  showed  there  is  a 
positive  correlation  between  income  and  the 
influence  of  the  willingness  to  participate  in  a 
clinical trial, but this is true especially among the 
wealthier  people  [17].  Our  results  show  that 
access  to  free  laboratory  investigation  is 
motivating. This prompts to some possibly health 
system  issues  that  may  vary  from  country  to 
country.  In  existing  UK  guidelines,  the  issues 
around  payments  to  clinicians  or  patients  are 
implied  rather  than  stated,  usually  linked  to  a 
discussion or a conflict of interest and disclosure 
of any such conflicts. Interviews with NHS health 
professionals,  mainly  research  active  clinicians, 
indicated  concerns  over  the  likely  effects  of 
payment.  While  reimbursement  of  expenses 
incurred  to  do  research  was  strongly  supported, 
payment to stimulate recruitment was not. Direct 
payment to clinicians, linked to recruitment or to 
research involvement was rare in publicly funded 
trials. A code of practice for any such payments 
was suggested, closely linked to the principles of 
Good Clinical Practice in research. Other factors 
such  as  interest  in  the  topic,  scope  for  patient 
benefit and good communication were considered 
the  most  important  motivations  for  research 
Table 3. Disincentives for participation in clinical trials 
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involvement. Interviews with the public indicated 
low levels of awareness of payments to clinicians 
linked  to  patient  involvement  in  trials,  and 
unanimous support for full disclosure of any such 
payments.  Interviews  with  research  managers  in 
the  pharmaceutical  industry  showed  greater 
familiarity  with  payments  for  research 
involvement, which, in recent years, has shifted to 
payment  to  institutions  rather  than  individual 
clinicians [18]. 
Study  drawbacks  include  the  fact  that 
patients were drawn from three different particular 
departments  of  rheumatology  and  there  was  a 
limited number. Further research is undoubtedly 
useful in determining whether our findings can be 
generalized  to  other  rheumatic  diseases  or  to 
populations  with  other  cultural  beliefs  about 
health care, research, and disability. 
The current study suggests that awareness  
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